Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1111/ases.12221 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Human collagen type I‑based scaffold retains human‑derived fibroblasts in a patient‑derived tumor xenograft mouse model.
Exp Ther Med
February 2025
Department of General Surgical Science, Division of Hepatobiliary and Pancreatic Surgery, Gunma University Graduate School of Medicine, Maebashi, Gunma 371-8511, Japan.
The present study aimed to investigate the role of a recombinant protein based on human collagen type I (RCPhC1) as a scaffold in maintaining the human tumor microenvironment within a patient-derived tumor xenograft (PDTX) model. RCPhC1, synthesized under animal component-free conditions, was explored for its potential to support the human-specific stroma associated with tumor growth. PDTX models were established using resected colorectal cancer liver metastasis specimens, and stromal cell populations from humans and mice were compared using three scaffolds: No scaffold (control), Matrigel and recombinant human collagen type I, across two passages.
View Article and Find Full Text PDFAdenylate cyclase 9 expression level is associated with hormone receptor-positive breast cancer and predicts patient prognosis.
Nagoya J Med Sci
November 2024
Department of Breast and Endocrine Surgery, Nagoya University Graduate School of Medicine, Nagoya, Japan.
Adenylate cyclase family members have recently received attention as novel therapeutic targets. However, the significance of adenylate cyclase 9 (ADCY9) in breast cancer has not been elucidated. Here, we evaluated expression in breast cancer (BC) cell lines, and polymerase chain reaction array analysis was performed to determine the correlations between expression levels and 84 tumor-associated genes.
View Article and Find Full Text PDFQuestionnaire on the surgical indications for intrahepatic cholangiocarcinoma administered to Japanese board-certified expert hepatobiliary and pancreatic surgeons and instructors.
J Hepatobiliary Pancreat Sci
January 2025
Department of Gastroenterological Surgery, Hiroshima University Hospital, Hiroshima, Japan.
Background: Treatment of intrahepatic cholangiocarcinoma (ICC) remains challenging owing to the lack of clear guidelines on surgical resection. The 2021 ICC guidelines have not fully resolved the ongoing debate between surgical and nonsurgical treatment options. This study aimed to identify trends and issues in ICC treatment strategies in the clinical field by surveying the attitudes of hepatobiliary and pancreatic (HBP) surgeons.
View Article and Find Full Text PDFBenefits of neoadjuvant chemotherapy with gemcitabine plus S-1 for resectable pancreatic ductal adenocarcinoma.
Mol Clin Oncol
February 2025
Department of Gastroenterological and Pediatric Surgery, Oita University Faculty of Medicine, Yufu, Oita 879-5593, Japan.
Currently, neoadjuvant chemotherapy (NAC) is usually performed even for resectable pancreatic ductal adenocarcinoma (rPDAC). The present study investigated the benefits of NAC with gemcitabine plus S-1 for rPDAC. The medical records of 170 patients diagnosed as having rPDAC based on preoperative imaging were reviewed retrospectively.
View Article and Find Full Text PDFCurative resection of multiple primary neuroendocrine tumors enabled by preoperative imaging: a case report.
J Surg Case Rep
January 2025
Department of Gastroenterological and Transplant Surgery, Graduate School of Biomedical and Health Sciences, Hiroshima University, 1-2-3 Kasumi, Minami-ku, Hiroshima 734-8551, Japan.
Neuroendocrine tumors (NENs) originate from neuroendocrine cells and predominantly occur in the gastrointestinal tract, lungs, and pancreas. Although the liver is commonly involved in NEN metastasis, primary hepatic neuroendocrine tumors (PHNETs) are rare. Herein, we report a case of a 52-year-old female who presented with slowly enlarging, cystic, multiple PHNETs.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!